Immunocore Holdings (IMCR) just reported second quarter 2026 earnings, with revenue of US$115.93 million and a reduced net loss of US$0.81 million, alongside updated five year survival data for KIMMTRAK.
See our latest analysis for Immunocore Holdings.
Immunocore Holdings’ latest earnings update and KIMMTRAK survival data come after a steady build in momentum, with a 30 day share price return of 6.42% and a 90 day share price return of 17.85%. However, the 3 year total shareholder return decline of 45.06% shows how long term holders have faced a more mixed experience.
If these results have you thinking about where growth focused healthcare companies could go next, it may be worth scanning other opportunities through the 43 healthcare AI stocks
With Immunocore Holdings shares up over the past quarter yet still lagging over three years, it is natural to weigh jumping in after this earnings and KIMMTRAK update against waiting for a cheaper entry. How does the current valuation stack up?
Most Popular Narrative: 48.9% Undervalued
Immunocore Holdings closed at $34, while the most followed narrative pegs fair value at $66.57. That creates a wide gap investors will want to understand.
Robust commercial uptake of KIMMTRAK, demonstrated by 32% YoY revenue growth, 13-month duration of therapy, and deeper community penetration, indicates durable market share and the potential for continued operating leverage as scale increases.
To value all of this in today's terms, we will use a discount rate of 7.49%, as per the Simply Wall St company report. Read the complete narrative.
Curious what justifies a fair value almost double the latest price? The narrative leans on rapid earnings expansion, richer margins and a steep future multiple. The exact mix might surprise you.
Result: Fair Value of $66.57 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, this Immunocore Holdings narrative can unravel if KIMMTRAK growth slows before other programs contribute meaningfully, or if rising R&D spend keeps profitability out of reach for longer.
Find out about the key risks to this Immunocore Holdings narrative.
Another View on Immunocore Holdings Valuation
The first narrative leans heavily on earnings growth and future profit margins. A simple sales based check tells a different story. Immunocore Holdings trades on a P/S of 4x, while the fair ratio is 3.7x and the US Biotechs industry sits much higher at 11.4x. That mix of slight expensiveness versus the fair ratio and a discount versus peers raises a practical question for you: Is the market underpricing future sales strength, or asking for a safety margin before paying up?
See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
Feeling encouraged by the tone of this Immunocore Holdings update, or still on the fence? Move quickly, review the data, and weigh the 3 key rewards.
Looking for more investment ideas beyond Immunocore Holdings?
Do not sit on the sidelines after reviewing Immunocore Holdings. Use the Simply Wall St screener to explore other stocks that fit your style before the crowd.
- Target higher quality upside by scanning companies that still look attractively priced through the 52 high quality undervalued stocks.
- Strengthen your income stream by reviewing stocks that have solid yields and staying power using the 8 dividend fortresses.
- Prioritise resilience by checking companies that pair sound balance sheets with steady fundamentals via the solid balance sheet and fundamentals stocks screener (48 results).
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com